How Testosterone Enanthate Affects LDL Cholesterol

Testosterone enanthate influences LDL through several competing pathways, and the net effect on LDL cholesterol is close to neutral:

1. Route of administration blunts the hepatic signal: Thompson (1989, PMID 2915439) tested the hypothesis that the lipid damage from anabolic steroids is driven by route rather than androgenic potency, and the data supported it. Intramuscular testosterone enanthate at 200 mg/week raised postheparin hepatic triglyceride lipase (HTGL) activity by only 25%, a change that was not statistically significant, whereas oral stanozolol at 6 mg/day raised it 123%. An injected ester releases androgen into systemic circulation rather than delivering a concentrated bolus to the liver on first pass.

2. Aromatisation to oestradiol protects LDL: Oestradiol upregulates hepatic LDL receptor expression, which increases clearance of LDL particles from the circulation. Testosterone aromatises, so it partly funds its own protection. Zmuda (1993, PMID 8487666) tested this directly by giving weightlifters testosterone enanthate with and without the aromatase inhibitor testolactone. Blocking aromatisation made every lipid change worse, not better: HDL fell 20% instead of 16%, apoA-I fell 15% instead of 12%, and HTGL activity rose 38% instead of 21%. This is why an aggressively dosed aromatase inhibitor can turn a lipid-neutral testosterone protocol into a lipid-hostile one.

3. Androgenic HTGL upregulation still occurs, mildly: The androgen receptor signal does upregulate hepatic lipase, which is why HDL falls on testosterone even at replacement doses. LDL is less sensitive to HTGL activity than HDL is, which is part of why the two markers diverge.

4. Particle number can move without cholesterol mass moving: Hartgens (2004, PMID 15155420) measured apolipoproteins in strength athletes on self-administered stacks and found total cholesterol did not change significantly while apolipoprotein B rose from 0.96 to 1.32 g/L. ApoB counts atherogenic particles; LDL cholesterol measures the cholesterol carried inside them. A normal LDL cholesterol result does not rule out a rise in particle number.

5. Lipoprotein(a) falls: Androgens reduce Lp(a), and testosterone is no exception. Hartgens (2004, PMID 15155420) documented Lp(a) falling from 189 to 32 U/L on stacks. This is the one genuinely favourable lipid effect of androgens, though its clinical weight against the HDL and ApoB changes is unresolved.

Replacement doses (100-200 mg/week):

• Whitsel (2001, PMID 11566455) pooled 19 studies covering 272 hypogonadal men receiving an average of 179 mg of intramuscular testosterone ester every 16 days for 6 months. LDL cholesterol fell by 5 mg/dL (95% CI: -8 to -1), total cholesterol fell 14 mg/dL, and HDL fell 4 mg/dL.
• In practice, most men on TRT see LDL within a few mg/dL of baseline in either direction.

200 mg/week in trained men (Thompson 1989, PMID 2915439):

• LDL cholesterol fell 16% over six weeks.
• HDL fell 9%, and the fall was confined to the less protective HDL3 subfraction.

Supraphysiological doses (300-600 mg/week):

• Bhasin (2001, PMID 11701431) gave graded doses up to 600 mg/week for 20 weeks under GnRH agonist suppression. HDL fell in a clear dose-dependent way; LDL was not among the markers reported to change significantly.
• The reasonable read is that testosterone dose drives HDL down hard without a matching LDL rise.

Testosterone stacked with orals (Webb 1984, PMID 6493049):

• Fourteen bodybuilders using 50-100 mg/day methandrostenolone plus 100-200 mg/week testosterone plus 100-200 mg/week nandrolone had LDL of 150 mg/dL on cycle versus 125 mg/dL off, and an LDL to HDL ratio of 6.0 versus 2.2.
• The LDL rise in that cohort tracks the oral, not the testosterone.

Timing: Any change is slow and modest. Lipids are worth checking at 8 to 12 weeks after starting or after a dose change, not at week 2.

Baseline: Full lipid panel before starting, and ApoB if your lab offers it. ApoB costs little and is the number that will actually change on a cycle.

On protocol:

• Recheck lipids 8 to 12 weeks after starting or after any dose change.
• Once stable on replacement doses, annually is reasonable for LDL, though HDL warrants closer attention.
• Recheck within 8 weeks of starting or increasing an aromatase inhibitor. Crushing oestradiol removes an LDL-protective mechanism and the panel will show it.

The result to actually look at:

• If LDL cholesterol is normal but ApoB is elevated, believe the ApoB. Hartgens (2004, PMID 15155420) showed exactly this pattern on androgens: unchanged cholesterol mass, sharply increased particle count.
• Non-HDL cholesterol (total minus HDL) is a free stand-in if ApoB is unavailable.

Blaming the right drug: If LDL rose after you added an oral to a testosterone base, the oral did it. Removing the oral is the intervention that works.

Protocol adjustments:

• Do not crush oestradiol. Zmuda (1993, PMID 8487666) demonstrated that blocking aromatisation worsens every lipid endpoint measured. If you are on an aromatase inhibitor for symptom control, use the smallest dose that controls symptoms and recheck lipids afterwards.
• Testosterone alone is not the compound to drop for LDL reasons. The oral 17-alpha-alkylated compounds in the stack are.

Standard lipid management works normally on TRT:

• Statins, ezetimibe and the usual dietary levers behave the same way in men on testosterone as in anyone else. Being on TRT is not a reason to avoid treating a genuinely high ApoB.
• Soluble fibre 10 to 25 g/day, replacing saturated fat with unsaturated, and 150 minutes/week of moderate cardio all remain first-line.

Context that matters more than the LDL number:

• Baggish (2017, PMID 28533317) compared 86 long-term anabolic steroid users against 54 non-using weightlifters and found higher coronary plaque volume in users, with lifetime dose strongly associated with atherosclerotic burden. A near-neutral LDL on testosterone is reassuring for that one marker; it is not a clean bill of cardiovascular health for long-term supraphysiological use.

Further reading: What steroids actually do to your cholesterol